Brief: Terns Pharmaceuticals Reports First Quarter 2023 Financial Results And Corporate Updates

Terns Pharmaceuticals

15/05/2023 13:07

Terns Pharmaceuticals Inc  TERN.O :
    * TERNS PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS AND CORPORATE UPDATES
    * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $298
MILLION
EXPECTED TO PROVIDE RUNWAY INTO 2026
    * TOP-LINE DATA FROM PHASE 2A DUET CLINICAL TRIAL OF
TERN-501
(THR-Β AGONIST) IN NASH EXPECTED IN Q3 OF 2023
    * QTRLY NET LOSS PER SHARE $0.31
    * Q1 EARNINGS PER SHARE VIEW $-0.27 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX8D2CGK 
Further company coverage:  TERN.O